Buy Research Peptides in Denver, CO

10mg · Lyophilized powder

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a segment of human gastric juice protein. First characterized in the early 1990s, it has been extensively studied in laboratory and animal models across more than 100 published papers. Research has investigated its effects on tissue repair processes, gastrointestinal mucosal integrity, and interactions with growth factor signaling pathways including the FAK-paxillin cascade and VEGF expression.

5mg · Lyophilized powder

TB-500 is a synthetic analog of Thymosin Beta-4 (Tβ4), a 43-amino acid peptide that occurs naturally in most mammalian tissues and cell types. Thymosin Beta-4 was first isolated from calf thymus tissue in the 1960s by Dr. Allan Goldstein at the National Institutes of Health. It operates primarily through its interaction with G-actin (globular actin), regulating actin polymerization which is fundamental to cell motility and migration. Published research has examined its effects in cardiac, dermal, corneal, and neurological models.

10mg · Lyophilized powder

KPV is a naturally occurring tripeptide fragment derived from the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH). Consisting of the amino acid sequence Lys-Pro-Val, it retains the anti-inflammatory properties of the parent hormone without melanogenic activity. Research has investigated its effects on inflammatory signaling pathways, particularly NF-κB inhibition, in skin and gastrointestinal tissue models.

10mg · Lyophilized powder

Semaglutide is a 31-amino acid GLP-1 receptor agonist based on the GLP-1(7-37) sequence with two key modifications: an Aib substitution at position 8 (protects against DPP-4 degradation) and a C-18 fatty diacid linker at position 26 (albumin binding for half-life extension). It has been studied in multiple large-scale clinical trial programs including SUSTAIN, PIONEER, and STEP, with over 20,000 total trial participants.

10mg · Lyophilized powder

Tirzepatide is a 39-amino acid dual GIP/GLP-1 receptor agonist based on the native GIP sequence. It incorporates a C-20 fatty diacid moiety for albumin binding and includes amino acid substitutions enabling GLP-1R cross-reactivity while maintaining GIPR activity. Studied in the SURPASS and SURMOUNT clinical trial programs with over 15,000 participants. The SURPASS-2 trial is the only published head-to-head comparison with semaglutide.

10mg · Lyophilized powder

Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously — the first peptide to engage all three pathways. Early phase clinical trial results published in the New England Journal of Medicine showed dose-dependent responses across metabolic parameters. The triple-agonist mechanism is a novel approach that goes beyond existing dual-agonist compounds.